Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4561 Prognostic value of pre-therapeutic and interim SSTR PET in patients with GI-NET receiving peptide receptor radionuclide therapy

Introduction: Baseline and interim (after 2 cycles) somatostatin receptor (SSTR)-directed PET/CTs are essential in patients with gastrointestinal neuroendocrine tumours (GI-NET) undergoing peptide radioreceptor therapy (PRRT).

Conference:

Presenting Author: Weber S

Authors: Weber S, Alwers S, Beissert M, Buck A, Werner R,

Keywords: somatostatin, PRRT, PFS, SUVmean,

#4553 The efficacy of “rechallenge” peptide receptor radionuclide therapy (PRRT) may be inferior to that of the initial PRRT, while the safety profile remains comparable

Introduction: Data on efficacy and adverse events of re-challenge PRRT (re-PRRT) for patients with gastrointestinal neuroendocrine tumours (GI-NETs) are limited.

Conference:

Presenting Author: Heinrich M

Authors: Heinrich M, Lutz F, Alwers S, Däubler C, Buck A,

Keywords: gastrointestinal neuroendocrine tumour, somatostatin receptor directed PET, laboratory parameters, Progression-free survival,

#4339 Dual threshold contouring for [68Ga]DOTATATE PET and correlation with overall survival (OS) in patients with neuroendocrine neoplasia (NEN)

Introduction: Accurate contouring for [68Ga]DOTATATE PET in NEN is challenging due to differing physiological uptake for the liver, spleen and other organs. This poses a significant problem for absolute thresholding algorithms using a single threshold, even if the threshold is based on liver uptake (as suggested for FDG PET by PERCIST). Improved contouring of PET to measure [68Ga]DOTATATE-avid tumour volume could help clinical translation of this potential biomarker.

Conference:

Presenting Author: Chan D

Authors: Chan D, Mokhtar S, Bernard E, Diakos C, Sabahi Z,

Keywords: prognostic biomarker, PET imaging, [68Ga]DOTATATE, Total Lesion Volume,

#3685 Somatostatin receptor imaging with difference positive rate of mice

Introduction: Majority of neuroendocrine neoplasms express SSTR2, and the pathological results of a single lesion cannot accurately reflect the expression of SSTR2 in other lesions because of heterogeneity.

Conference:

Presenting Author:

Authors: Qing X, Xiangxi M, Zhi Y, Jiangyuan Y,

Keywords: neuroendocrine neoplasm, somatostatin receptor, imaging, immunohistochemistry,

#3470 Molecular Imaging Tumor Volume of Somatostatin Receptor (MITVSSR) on 68Ga-DOTATATE PET/CT, dosimetry and predictors of overall survival and response in unresectable neuroendocrine neoplasms treated with Peptide Receptor Radionuclide Therapy (PRRT)

Introduction: PRRT delivers targeted radionuclide therapy to Neuroendocrine Neoplasms (NENs) with high SSR expression.

Conference:

Presenting Author:

Authors: Alipour R, Jackson P, Callahan J, Bressel M, Hogg A,

Keywords: PRRT, dosimetry, survival, response,